MOLLY CAHILL: Open Payments
NPI 1336104702 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,766 in 30 payments from 9 companies in 2025. Trend: 2023 $1,216 · 2024 $666 · 2025 $5,766
Speaker / faculty: $3,850Food & beverage: $1,008Consulting: $908
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 15 | $4,439 |
| Novo Nordisk Inc | 6 | $993 |
| AstraZeneca Pharmaceuticals LP | 2 | $140 |
| AKEBIA THERAPEUTICS INC | 1 | $108 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 2 | $8 |
Products named: TAVNEOS, Rivfloza, KRYSTEXXA, LOKELMA, Vafseo, Ozempic, TERLIVAZ, LIVTENCITY.
Industry payments across MO — which companies pay providers there.
